Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Leading scientists to discuss research applications for therapeutic cloning

21.10.2004


University of Pittsburgh’s Gerald Schatten, Ph.D., joins South Korean researchers for symposium at 60th Annual Meeting of the American Society for Reproductive Medicine



As members of the United Nations General Assembly are soon to vote on the future of cloning research, possibly within days, leading scientists will be conducting a symposium discussion on the status of current work in cloning and its potential for the emerging field of regenerative medicine.

Gerald Schatten, Ph.D., professor of obstetrics, gynecology and reproductive sciences and cell biology and physiology at the University of Pittsburgh School of Medicine, will join South Korean researchers Woo Suk Hwang, D.V.M., Ph.D., and Shin Yong Moon, M.D., in a panel discussion of scientific and ethical issues surrounding cloning research on Wednesday, Oct. 20, at the 60th annual meeting of the American Society for Reproductive Medicine. Scientific sessions will take place Oct. 16-20 at the Pennsylvania Convention Center in Philadelphia.


In February, Drs. Hwang and Moon from Seoul National University, reported the successful harvesting of human embryonic stem cells from a cloned embryo. The cloning symposium, called "Assisted Regenerative Medicine: The Future of ART?" and chaired by Linda Giudice, M.D., Ph.D., of Stanford University, will take place on Wednesday, Oct. 20. "Human reproductive cloning is unsafe, unethical and ought to be illegal everywhere in the world," said Dr. Schatten, who also is director of the Pittsburgh Development Center at the Magee-Womens Research Institute. "But a ban on all forms of human cloning sends the wrong signal to the scientific community; it stigmatizes the research and will slow the pace of discoveries for decades to come."

Dr. Schatten, who testified before U.N. delegates on the issue in June, is close to the debate because he has been trying to clone primates, which belong to the same overall species classification as humans. The implications of any success for the prospects of human cloning are clear, and Dr. Schatten is exploring ways to make sure that if he succeeds, others won’t be able to use his work to advance human cloning for reproductive purposes.

In the U.N., the United States is pressing for a ban on all forms of human cloning, while Belgium heads a faction seeking a ban on reproductive cloning but with the option for countries to approve therapeutic cloning. In 2001, Britain became the first country to legalize research cloning. Researchers hope stem cells derived from therapeutic cloning research will revolutionize medicine by providing better treatments for disorders such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, heart disease, stroke, diabetes, spinal cord injuries and genetic diseases.

While the hopes are real, scientific findings remain ambiguous concerning actual benefits for patients using stem cells for therapeutic purposes. "Will therapeutic cloning create immune matching? It’s unclear. At this point, we don’t even know if human embryonic stem cells are safe, let alone effective," said Dr. Schatten. "What’s important is that research be allowed to continue so we can find out."

Currently, conflicting policies internationally allow different stages of research in human and animal cloning in different countries. The United Kingdom restricts animal work but allows research on human embryos. In the United States, animal work is allowed but work on human embryonic stem cells is restricted to cell lines in existence prior to Aug. 9, 2001. Related legislation varies from state to state, with Pennsylvania being among the most restrictive. South Korea allows therapeutic cloning research but human reproductive cloning is illegal there.

"Perhaps, in a similar fashion to debates surrounding organ donation, it will be challenging to achieve political consensus until the therapeutic benefits of cloning research are clearly demonstrated," said Dr. Schatten, calling for responsible legislation in the United States and warning that a ban on all cloning research could simply move the science offshore or to privately funded efforts not subject to U.S. regulation. Responsible clinical trials also need to be held soon, perhaps by 2008, Dr. Schatten adds.

Michele Baum | EurekAlert!
Further information:
http://upmc.edu

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>